Iproteos wins the Expoquimia R+D+I Award in the Biotechnology category

Ernest Giralt i Teresa Tarragó, fundadors d'Iproteos, durant l'acte del lliurament del premi.
Ernest Giralt i Teresa Tarragó, fundadors d'Iproteos, durant l'acte del lliurament del premi.
Research
(09/10/2014)

The Catalan biotech Iproteos —a spin-off of the University of Barcelona (UB) and the Institute for Research in Biomedicine (IRB Barcelona) located at the Barcelona Science Park (PCB)— has won the Expoquimia R+D+I Award in the Biotechnology category for the development of IPR19, a new drug to stop the progression and reverse the cognitive deficits associated with schizophrenia. Iproteos is a spin-off created in 2011 by two Catalan leading scientists in the field of therapeutic peptides: Ernest Giralt, professor from the Department of Organic Chemistry of UB, and Teresa Tarrago, researcher at IRB Barcelona. The company, which expects to begin clinical trials of the compound in 2016, emerged from the transfer of a technology developed at UB and IRB Barcelona, with the strategic participation of the Bosch i Gimpera Foundation (FBG). It is important to remember that the University of Barcelona (UB) participated in the fair Expoquimia 2014 in which the Barcelona Knowledge Campus (BKC), one of UBʼs campus of International excellence, presented the BKC Chemistry.

Ernest Giralt i Teresa Tarragó, fundadors d'Iproteos, durant l'acte del lliurament del premi.
Ernest Giralt i Teresa Tarragó, fundadors d'Iproteos, durant l'acte del lliurament del premi.
Research
09/10/2014

The Catalan biotech Iproteos —a spin-off of the University of Barcelona (UB) and the Institute for Research in Biomedicine (IRB Barcelona) located at the Barcelona Science Park (PCB)— has won the Expoquimia R+D+I Award in the Biotechnology category for the development of IPR19, a new drug to stop the progression and reverse the cognitive deficits associated with schizophrenia. Iproteos is a spin-off created in 2011 by two Catalan leading scientists in the field of therapeutic peptides: Ernest Giralt, professor from the Department of Organic Chemistry of UB, and Teresa Tarrago, researcher at IRB Barcelona. The company, which expects to begin clinical trials of the compound in 2016, emerged from the transfer of a technology developed at UB and IRB Barcelona, with the strategic participation of the Bosch i Gimpera Foundation (FBG). It is important to remember that the University of Barcelona (UB) participated in the fair Expoquimia 2014 in which the Barcelona Knowledge Campus (BKC), one of UBʼs campus of International excellence, presented the BKC Chemistry.